{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-015346","form_type":"8-K","ticker":"LIXT","cik":"0001335105","company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","filed_at":"2025-06-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.008674+00:00","generated_at":"2026-05-19T04:25:27.204546+00:00","sec_items":["1.01","5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Lixte appoints Geordan Pursglove as CEO, contingent on Nasdaq financing by July 3","bullets":["Geordan Pursglove appointed CEO and Chairman; Bastiaan van der Baan resigns as CEO, remains President and CSO.","Employment agreement with Pursglove has $240K annual salary, plus potential bonus and stock option grant for 350K shares.","Van der Baan's existing stock option for 250K shares fully vested; exercise period extended to one year after service ends.","Pursglove's appointment automatically terminates if Lixte fails to complete a financing enabling Nasdaq listing by July 3, 2025.","If financing condition not met, van der Baan to be reinstated as CEO and Chairman, and Pursglove's option grant cancelled."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-015346","json":"https://secwatch.observer/filing/0001641172-25-015346.json","markdown":"https://secwatch.observer/filing/0001641172-25-015346.md","text":"https://secwatch.observer/filing/0001641172-25-015346.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1335105/000164117225015346/0001641172-25-015346-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1335105/000164117225015346/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T04:25:27.204546+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6ef6226f50","claim":"Bastiaan van der Baan departed as President and Chief Scientific Officer at LIXTE BIOTECHNOLOGY HOLDINGS, INC..","evidence_excerpt":"Bastiaan van der Baan resigned as Chairman of the Board of Directors and Chief Executive Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1335105/000164117225015346/0001641172-25-015346-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned as Chairman and Chief Executive Officer"},{"label":"Role","value":"President and Chief Scientific Officer"}],"fact_type":"executive_change"},{"claim_id":"8244f3f343","claim":"Geordan Pursglove was appointed as Chief Executive Officer and Chairman at LIXTE BIOTECHNOLOGY HOLDINGS, INC..","evidence_excerpt":"effective June 16, 2025, Geordan Pursglove was appointed as the Company’s Chairman of the Board of Directors and Chief Executive Officer,","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1335105/000164117225015346/0001641172-25-015346-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer and Chairman"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}